O	0	4	FACT
O	4	5	:
O	6	8	an
O	9	13	open
O	13	14	-
O	14	19	label
O	20	30	randomized
O	31	36	phase
O	37	40	III
O	41	46	study
O	47	49	of
B-intervention	50	61	fulvestrant
I-intervention	62	65	and
I-intervention	66	77	anastrozole
O	78	80	in
O	81	92	combination
O	93	101	compared
O	102	106	with
B-control	107	118	anastrozole
I-control	119	124	alone
O	125	127	as
O	128	133	first
O	133	134	-
O	134	138	line
O	139	146	therapy
O	147	150	for
O	151	159	patients
O	160	164	with
O	165	173	receptor
O	173	174	-
O	174	182	positive
O	183	197	postmenopausal
O	198	204	breast
O	205	211	cancer
O	211	212	.

O	213	215	To
O	216	223	compare
O	224	227	the
O	228	234	effect
O	235	237	of
O	238	245	therapy
O	246	250	with
O	251	262	anastrozole
O	263	269	versus
O	270	271	a
O	272	283	combination
O	284	286	of
O	287	298	fulvestrant
O	299	302	and
O	303	314	anastrozole
O	315	317	in
O	318	323	women
O	324	326	in
O	327	332	first
O	333	340	relapse
O	341	343	of
O	344	353	endocrine
O	353	354	-
O	354	364	responsive
O	365	371	breast
O	372	378	cancer
O	378	379	.

B-eligibility	380	394	Postmenopausal
I-eligibility	395	400	women
I-eligibility	400	401	,
I-eligibility	402	404	or
I-eligibility	405	418	premenopausal
I-eligibility	419	424	women
I-eligibility	425	434	receiving
I-eligibility	435	436	a
I-eligibility	437	449	gonadotropin
I-eligibility	449	450	-
I-eligibility	450	459	releasing
I-eligibility	460	467	hormone
I-eligibility	468	475	agonist
I-eligibility	475	476	,
I-eligibility	477	481	with
I-eligibility	482	490	estrogen
I-eligibility	491	499	receptor
I-eligibility	499	500	-
I-eligibility	501	504	and
I-eligibility	504	505	/
I-eligibility	505	507	or
I-eligibility	508	520	progesterone
I-eligibility	521	529	receptor
I-eligibility	529	530	-
I-eligibility	530	538	positive
I-eligibility	539	546	disease
I-eligibility	547	549	at
I-eligibility	550	555	first
I-eligibility	556	563	relapse
I-eligibility	564	569	after
I-eligibility	570	577	primary
I-eligibility	578	587	treatment
I-eligibility	588	590	of
I-eligibility	591	600	localized
I-eligibility	601	608	disease
O	609	613	were
O	614	618	open
O	618	619	-
O	619	624	label
O	625	633	randomly
O	634	642	assigned
O	643	645	to
O	646	647	a
O	648	659	fulvestrant
O	660	667	loading
O	668	672	dose
O	673	674	(
O	674	676	LD
O	676	677	)
O	678	685	regimen
O	686	694	followed
O	695	697	by
O	698	705	monthly
O	706	715	injection
O	716	720	plus
O	721	722	1
O	723	725	mg
O	726	728	of
O	729	740	anastrozole
O	741	746	daily
O	747	749	or
O	750	752	to
O	753	754	1
O	755	757	mg
O	758	760	of
O	761	772	anastrozole
O	773	778	daily
O	779	784	alone
O	784	785	.

O	786	789	The
O	790	797	primary
O	798	801	end
O	802	807	point
O	808	811	was
B-outcome-Measure	812	816	time
I-outcome-Measure	817	819	to
I-outcome-Measure	820	831	progression
I-outcome-Measure	832	833	(
I-outcome-Measure	833	836	TTP
I-outcome-Measure	836	837	)
O	837	838	.

O	839	841	In
O	842	845	all
O	845	846	,
B-total-participants	847	850	514
O	851	856	women
O	857	861	were
O	862	870	randomly
O	871	879	assigned
O	880	882	to
O	883	894	fulvestrant
O	895	899	plus
O	900	911	anastrozole
O	912	913	(
O	913	925	experimental
O	926	929	arm
O	929	930	;
O	931	932	n
O	933	934	=
B-intervention-participants	935	938	258
O	938	939	)
O	940	942	or
O	943	954	anastrozole
O	955	956	(
O	956	964	standard
O	965	968	arm
O	968	969	;
O	970	971	n
O	972	973	=
B-control-participants	974	977	256
O	977	978	)
O	978	979	.

O	980	993	Approximately
O	994	997	two
O	998	1004	thirds
O	1005	1008	had
O	1009	1017	received
O	1018	1026	adjuvant
O	1027	1040	antiestrogens
O	1040	1041	,
O	1042	1045	but
O	1046	1050	only
O	1051	1056	eight
O	1057	1068	individuals
O	1069	1072	had
O	1073	1081	received
O	1082	1084	an
O	1085	1094	aromatase
O	1095	1104	inhibitor
O	1104	1105	.

B-outcome	1106	1112	Median
I-outcome	1113	1116	TTP
O	1117	1120	was
B-iv-cont-median	1121	1123	10
I-iv-cont-median	1123	1124	.
I-iv-cont-median	1124	1125	8
O	1126	1129	and
B-cv-cont-median	1130	1132	10
I-cv-cont-median	1132	1133	.
I-cv-cont-median	1133	1134	2
I-cv-cont-median	1135	1141	months
O	1142	1144	in
O	1145	1148	the
O	1149	1161	experimental
O	1162	1168	versus
O	1169	1177	standard
O	1178	1181	arm
O	1181	1182	,
O	1183	1195	respectively
O	1196	1197	(
O	1197	1203	hazard
O	1204	1209	ratio
O	1210	1211	[
O	1211	1213	HR
O	1213	1214	]
O	1215	1216	=
O	1217	1218	0
O	1218	1219	.
O	1219	1221	99
O	1221	1222	;
O	1223	1225	95
O	1225	1226	%
O	1227	1229	CI
O	1229	1230	,
O	1231	1232	0
O	1232	1233	.
O	1233	1235	81
O	1236	1238	to
O	1239	1240	1
O	1240	1241	.
O	1241	1243	20
O	1243	1244	;
O	1245	1246	P
O	1247	1248	=
O	1249	1250	.
O	1250	1252	91
O	1252	1253	)
O	1253	1254	;
B-outcome	1255	1261	median
I-outcome	1262	1269	overall
I-outcome	1270	1278	survival
O	1279	1282	was
B-iv-cont-median	1283	1285	37
I-iv-cont-median	1285	1286	.
I-iv-cont-median	1286	1287	8
O	1288	1291	and
B-cv-cont-median	1292	1294	38
I-cv-cont-median	1294	1295	.
I-cv-cont-median	1295	1296	2
I-cv-cont-median	1297	1303	months
O	1303	1304	,
O	1305	1317	respectively
O	1318	1319	(
O	1319	1321	HR
O	1322	1323	=
O	1324	1325	1
O	1325	1326	.
O	1326	1327	0
O	1327	1328	;
O	1329	1331	95
O	1331	1332	%
O	1333	1335	CI
O	1335	1336	,
O	1337	1338	0
O	1338	1339	.
O	1339	1341	76
O	1342	1344	to
O	1345	1346	1
O	1346	1347	.
O	1347	1349	32
O	1349	1350	;
O	1351	1352	P
O	1353	1354	=
O	1355	1356	1
O	1356	1357	.
O	1357	1359	00
O	1359	1360	)
O	1360	1361	.

O	1362	1372	Incidences
O	1373	1375	of
O	1376	1388	prespecified
B-outcome	1389	1396	adverse
I-outcome	1397	1403	events
I-outcome	1404	1405	(
I-outcome	1405	1408	AEs
I-outcome	1408	1409	)
O	1410	1414	were
O	1415	1422	similar
O	1422	1423	.

B-outcome	1424	1427	Hot
I-outcome	1428	1435	flashes
O	1436	1440	were
O	1441	1445	more
O	1446	1452	common
O	1453	1455	in
O	1456	1459	the
O	1460	1472	experimental
O	1473	1476	arm
O	1476	1477	:
B-iv-bin-abs	1478	1480	63
O	1481	1489	patients
O	1490	1491	(
B-iv-bin-percent	1491	1493	24
I-iv-bin-percent	1493	1494	.
I-iv-bin-percent	1494	1495	6
I-iv-bin-percent	1495	1496	%
O	1496	1497	)
O	1498	1504	versus
B-cv-bin-abs	1505	1507	35
O	1508	1516	patients
O	1517	1518	(
B-cv-bin-percent	1518	1520	13
I-cv-bin-percent	1520	1521	.
I-cv-bin-percent	1521	1522	8
I-cv-bin-percent	1522	1523	%
O	1523	1524	)
O	1525	1527	in
O	1528	1531	the
O	1532	1540	standard
O	1541	1544	arm
O	1545	1546	(
O	1546	1547	P
O	1548	1549	=
O	1550	1551	.
O	1551	1555	0023
O	1555	1556	)
O	1556	1557	.

B-outcome	1558	1563	Death
I-outcome	1564	1569	owing
I-outcome	1570	1572	to
I-outcome	1573	1576	AEs
O	1577	1580	was
O	1581	1589	reported
O	1590	1592	in
B-iv-bin-abs	1593	1595	11
O	1596	1597	(
B-iv-bin-percent	1597	1598	4
I-iv-bin-percent	1598	1599	.
I-iv-bin-percent	1599	1600	3
I-iv-bin-percent	1600	1601	%
O	1601	1602	)
O	1603	1606	and
B-cv-bin-abs	1607	1611	five
O	1612	1620	patients
O	1621	1622	(
B-cv-bin-percent	1622	1623	2
I-cv-bin-percent	1623	1624	.
I-cv-bin-percent	1624	1625	0
I-cv-bin-percent	1625	1626	%
O	1626	1627	)
O	1628	1630	in
O	1631	1634	the
O	1635	1647	experimental
O	1648	1654	versus
O	1655	1663	standard
O	1664	1667	arm
O	1667	1668	,
O	1669	1681	respectively
O	1681	1682	.

O	1683	1694	Fulvestrant
O	1695	1696	(
O	1696	1699	250
O	1700	1702	mg
O	1703	1704	+
O	1705	1707	LD
O	1708	1715	regimen
O	1715	1716	)
O	1717	1719	in
O	1720	1731	combination
O	1732	1736	with
O	1737	1748	anastrozole
O	1749	1756	offered
O	1757	1759	no
O	1760	1768	clinical
O	1769	1777	efficacy
O	1778	1787	advantage
O	1788	1792	over
O	1793	1804	anastrozole
O	1805	1816	monotherapy
O	1817	1819	in
O	1820	1824	this
O	1825	1835	population
O	1836	1838	of
O	1839	1850	individuals
O	1851	1855	with
O	1856	1857	a
O	1858	1868	relatively
O	1869	1873	high
O	1874	1884	proportion
O	1885	1887	of
O	1888	1896	previous
O	1897	1905	adjuvant
O	1906	1918	antiestrogen
O	1919	1927	exposure
O	1927	1928	.
